Every Value-Based ABA Model Bets on Fewer Hours

The Shared Wager

The three most developed value-based arrangements in autism therapy look nothing alike on paper. One pays a fixed monthly amount per member and grades quality using an adaptive behavior scale. One pays a monthly case rate that varies by care track, with bonuses for meeting access and outcome targets. One is a telehealth provider arguing that the whole field should put fees at risk in exchange for results.

What they share is more revealing than what separates them. Each is built on the proposition that ABA currently delivers more hours than children need, and that a provider paid differently would deliver fewer. Kyo Autism Therapy reports hours titrated down as children progress. Cortica says its model uses half the volume of standard ABA therapy. AnswersNow reports positive outcomes with 85% fewer hours. The efficiency claim is the business model.

That is a substantial bet on a proposition the published literature has not settled, and every figure above comes from the company making it.

Kyo and Magellan: Capitation on a Scale

The California arrangement between Kyo Autism Therapy and Magellan Healthcare is the longest-running of the three, operating for more than three years. Magellan pays a capitated amount per member per month, and longitudinal quality is assessed using the Vineland Adaptive Behavior Scales. Kyo reports that roughly 80% of patients show progress on Vineland measures, with care hours decreasing as children improve. Magellan reported in 2023 that 74% of members receiving ABA showed improved outcomes.

Deepa Shah, Kyo’s chief growth officer, has been candid that the structure is not self-executing. Value-based care can drive quality but is not guaranteed if it is not designed well, she said at an industry conference in March, and narrowly defined or overly prescriptive metrics can distort care. The arrangement’s weakness is the same as its strength: it rests on a single instrument, and that instrument’s fitness for tracking change during treatment is contested in the research literature.

Cortica and Point32Health: Tracks and Bonuses

Cortica took a different route by changing the clinical model first. The company delivers what it calls whole-child care through an interdisciplinary team of neurologists, behavior analysts, speech pathologists and occupational therapists, combining medical care, developmental therapies, ABA and family counseling under one roof. Its arrangement with Point32Health, the Massachusetts insurer formed from the merger of Tufts Health Plan and Harvard Pilgrim, covers commercial and Medicaid members and is divided into four tracks of increasing scope and intensity.

The payment mechanics are more granular than capitation. Point32Health pays a monthly case rate that depends on the child’s track, with a pay-for-performance layer of bonuses for meeting predefined outcome and process goals, according to Jill Borrelli, the insurer’s vice president of behavioral health. The contract also carries speed-to-care expectations: a care plan assessment within an average of 15 days of diagnosis, and treatment beginning within 15 days of that assessment. Against research findings showing average ABA wait times of roughly three and a half months, those are demanding terms.

Quality is tracked through a whole-child scorecard remeasured every six months against standards recommended by the International Consortium for Health Outcomes Measurement, alongside process measures including speed to care and Net Promoter scores. “For our clinicians to be able to think about the quality of care above all else, and that’s what we are measuring, that’s what matters to the payer and the family,” said Suzanne Goh, Cortica’s co-founder and chief medical officer.

Investors have backed the approach. Morgan Health, the JPMorgan Chase unit, co-led an $80 million round in Cortica in November 2024 with Nexus NeuroTech Ventures and the Autism Impact Fund, specifically to expand value-based contracts and add guarantees for evaluation, diagnosis, treatment speed, and clinical outcomes. Cortica works with 35 payers across value-based and fee-for-service relationships, operates in eight states, and said it would serve more than 24,000 patients and families in 2024. Morgan Health chief executive Dan Mendelson said the appeal was a provider willing to take on risk: the unit wants organizations that will take responsibility for quality and cost.

Cortica’s own published claims are the ones to hold at arm’s length. The company says its model improves outcomes across conditions co-occurring with autism, uses 50% of standard ABA therapy volumes, limits antipsychotic and stimulant prescribing, reduces emergency and inpatient admissions, and produces 34% in annual savings per patient. Those are company figures describing the company’s own model.

Each model differs in how it pays. All three assume the field currently treats too much. That assumption, not the payment mechanism, is what value-based care in ABA is actually testing.

AnswersNow: Putting Fees at Risk

The third position is argumentative rather than contractual. Jeff Beck, chief executive of the virtual provider AnswersNow, has used the trade and business press to press for outcomes-based contracting as the field’s fastest route to self-policing before regulators narrow it further. His prescription bundles four changes: training caregivers so that progress continues between sessions; placing more direct care in the hands of master’s-level analysts rather than technicians; delivering treatment in natural settings, including the home and via video; and tying compensation to results rather than hours.

Beck reports that virtually delivered, analyst-led care at his company has produced positive clinical outcomes, with 85% fewer hours and 75% lower cost. Those are the most dramatic efficiency figures any of the three has offered; they are self-reported by a company selling the model and have not been independently verified. His structural argument stands on firmer ground than his numbers: it was the fee-for-service model, he has written, that drew private equity into autism therapy in the first place.

AT A GLANCE

SOURCES & REFERENCES